ArticleThe journal of headache and pain2025
Prevalence, characteristics and management of migraine patients with triptan failure in primary care: the EMR France-Mig study.
Article in The journal of headache and pain, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Genetic Basis of the Negative Response to the Use of Triptans for the Treatment of Migraine-A Systematic Review and Meta-Analysis.Brain and behavior · 2025Pooled it
- Time Course of Rimegepant Effect for Acute Treatment of Migraine in Adults Unsuitable for Triptans: Exploratory Endpoints from a Phase 4, Randomized, Double-Blind, Placebo-Controlled Study.Neurology and therapy · 2026Article
- Review
- Atogepant reduces triptan use: a pharmacoeconomic analysis in migraine prevention.The journal of headache and pain · 2026Observational
- Migraine epidemiology, comorbidities and therapeutic landscape: a national population-based study.Frontiers in neurologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe most used treatments for migraine attacks are triptans, yet a considerable proportion of the population develops treatment failure over time due to ineffectiveness, side effects, and/or contraindications. The aim of the France-Mig study was to quantify the population with triptan failure due to ineligibility or resistance, in the primary care setting, and describe their therapeutic management.
methodsThe France-Mig study was a retrospective analysis of a cohort of patients suffering from migraine in 2022 identified using data from the IQVIA electronic medical records (EMR). Patients were identified using either a migraine diagnosis (ICD-10 G43) or a prescription for migraine-specific drugs. Triptan failure was defined as patients with triptan ineligibility (having a contraindication listed in the summary of product characteristics of triptan or aged over 65 years old) or triptan resistance (unsuccessful intake of two different triptans, following the 2022 European Headache Federation consensus definition).
resultsA total of 16,888 adult patients with migraine diagnosis or migraine-specific treatment prescribed in 2022 and with at least 5 years of look back period were included (after extrapolation, it was estimated that 1,440,169 adults consulted a general practitioner in primary care for migraine in 2022 in metropolitan France, which corresponds to 2.78% of the French population). Among the 16,888 patients fulfilling inclusion criteria, 4,509 (26.7%) were identified as having triptan failure, including 4,024 (23.8%) ineligible patients (1,364 [8.1%] with cardiovascular contraindications for triptans, 700 [4.1%] with non-cardiovascular contraindications, 2,055 [12.2%] with age superior or equal to 65 years) and 604 (3.6%) with triptan resistance. A total of 1,384 (53.9%) patients with ineligibility were prescribed a triptan (after their ineligibility). Among patients with triptan resistance, 273 (45.2%) were prescribed at least 3 different triptan molecules and 41 (6.8%) were prescribed at least 4 different triptan molecules.
conclusionsTriptans failed in more than a quarter of patients. The high proportion of patients treated with triptan despite contraindication showed a substantial unmet therapeutic need, warranting further research and tailored approaches to improve patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.